Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07116057 · ClinicalTrials.gov registry record · Phase 1
MOv19-BBz CAR T Cells in FRa+ Cancers
A Phase 1 study of Metastatic Non Small Cell Lung Cancer and Recurrent Lung Non-Small Cell Carcinoma, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07116057: Recruiting Phase 1 study of Metastatic Non Small Cell Lung Cancer and Recurrent Lung Non-Small Cell Carcinoma, sponsored by University of Pennsylvania.
NCT07116057 is a Phase 1 study of Metastatic Non Small Cell Lung Cancer and Recurrent Lung Non-Small Cell Carcinoma that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 10 participants, below the 382-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07116057, a Phase 1 study of Metastatic Non Small Cell Lung Cancer and Recurrent Lung Non-Small Cell Carcinoma, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers. This study will be initiated in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) only. Subjects will receive a single dose of MOv19-BBz CAR T cells via intrapleural infusion following lymphodepleting chemotherapy. Subjects without an existing intra-pleural catheter will have a temporary pleural catheter placed for the study. Subjects may initiate treatment with commercial checkpoint inhibitors per routine care beginning at least 28 days after receiving MOv19-BBz CAR T cells.
Primary Outcome
Type, frequency, severity, and attribution of adverse events.
Conditions Studied
Interventions
- BIOLOGICAL MOv19-BBz CAR T cells
- DRUG Cyclophosphamide/Fludarabine
- DEVICE FRa Expression Testing
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-10-07 |
| Est. Completion | 2040-10 |
| Phase | Phase 1 |
What NCT07116057 shows while recruiting
NCT07116057 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 382-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which MOv19-BBz CAR T cells is the first listed.
NCT07116057 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07116057 about?
NCT07116057 is a clinical study titled "MOv19-BBz CAR T Cells in FRa+ Cancers". This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers. This study will be initiated in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) only...
What is the current status of trial NCT07116057?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-10-07. Estimated completion is 2040-10.
What conditions does trial NCT07116057 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma.
What interventions are being tested in trial NCT07116057?
The interventions under investigation include: MOv19-BBz CAR T cells (BIOLOGICAL), Cyclophosphamide/Fludarabine (DRUG), FRa Expression Testing (DEVICE).
Who is sponsoring clinical trial NCT07116057?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07116057 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07116057's enrollment target sits among peer trials
10 31st of 31 higher than 1 of 31 other Metastatic Non Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Non Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
RECRUITING · Phase 1
-
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI